Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 11/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.52 |
| ▸ | PRKDC | P78527 | 2/20 | 0.52 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.48 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL189233 | 0.95 | PIK3CG (0.60) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL13416205 | 0.95 | PIK3CG (0.58) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL13416114 | 0.93 | PIK3CG (0.58) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL16091812 | 0.92 | PIK3CG (0.67) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL13416358 | 0.91 | PIK3CG (0.55) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL13416517 | 0.91 | PIK3CG (0.55) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL12402664 | 0.90 | PIK3CG (0.58) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL188938 | 0.90 | PIK3CG (0.60) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL13416134 | 0.89 | PIK3CG (0.67) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL13416093 | 0.88 | PIK3CD (0.59) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | PIK3CG 5/4885PIK3CD 2/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.